AUM Biosciences attended the “US-China Biopharma Innovation & Investment Summit” in Shanghai on October 22 – 23, 2018

Shanghai, 22 – 23 October 2018

AUM Biosciences attended the 2-day US-China Biopharma Innovation & Investment Summit that was held at the Shanghai Four Seasons, in Shanghai.

China’s biotech scene has been exploding over the past 2 years, presenting start-ups, especially those from Asia, with huge opportunities. The conference brings together movers and shakers in the emerging healthcare markets with a forecast on drug innovation and a special focus on the regulatory scene.

More information about the event can be found here.

For any additional queries, please contact

About AUM Biosciences

AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. Dedicated to unlocking the value in innovation, AUM harnesses the power of precision medicine and digital health to support patients, physicians and partners. AUM focuses on earlystage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets.

AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs. AUM Biosciences is led by a highly-experienced management team with over 75 years of high-quality oncology drug development experience combined.

Headquartered in Singapore, AUM is strategically positioned to work, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally. AUM is the recipient of Frost & Sullivan’s 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year. For more information, please visit